SLN.L Share News (SLN)

Silence Therapeutics Files Interim Injunction Against Alnylam

LONDON (Alliance News) - Silence Therapeutics PLC said Wednesday it filed a cross-border interim injunction application to stop Alnylam Pharmaceuticals Inc from commercialising patisiran drug drug

Silence Therapeutics losses deepen as lead drugs near trials

(Sharecast News) - Biotechnology firm Silence Therapeutics shares fell on Tuesday after reporting a first half loss after tax of £8.7m, up 57%, due to costs associated with bringing its two lead programmes towards the clinic.

Silence Therapeutics Interim Loss Widens As Research Costs Surge

LONDON (Alliance News) - Silence Therapeutics PLC said Tuesday that its loss for the first half of the financial year widened as research & development costs jumped.Shares in the were a

Silence Therapeutics Executive Chair Jenkins Steps Down

LONDON (Alliance News) - Silence Therapeutics PLC said Monday that Executive Chair Annalisa Jenkins will be leaving her role with immediate effect after 11 months into the role.The company

Silence Therapeutics Appoints Dave Lemus As Non-Executive Director

LONDON (Alliance News) - Silence Therapeutics PLC said Thursday it appointed Dave Lemus to the board as non-executive director effective immediately.The company focused on the discovery and

Silence Therapeutics Gets Promising Data From Iron Disorder Treatment

LONDON (Alliance News) - Silence Therapeutics PLC said Friday its compound for the treatment of iron overload disorders may "provide a safe, effective and patient-friendly therapeutic Project

Silence Therapeutics Boss Ali Mortazavi Leaves After Six Years

LONDON (Alliance News) - Silence Therapeutics PLC on Monday announced the departure of Chief Executive Ali Mortazavi with immediate effect after six years in the job.He will be replaced as

Silence Therapeutics Files Patent Violation Claim Against Alnylam

LONDON (Alliance News) - Silence Therapeutics PLC said Tuesday it has begun patent infringement proceedings in Portugal against Alnylam Pharmaceutical a a

Silence Therapeutics Loss Narrows On Asset Sale As Ponders US Listing (ALLIPO)

LONDON (Alliance News) - Silence Therapeutics PLC said Tuesday its full year loss narrowed after profitable share sales of its NASDAQ-listed peer Arrowhead Pharmaceutical Inc

Silence confirms minority stake in Arrowhead Pharmaceuticals

(ShareCast News) - Discoverer, deliverer and developer of novel RNA therapeutics for the treatment of serious diseases, Silence Therapeutics updated the market on its announcement on 9 January regarding the acquisition of a minority stake in Arrowhead Pharmaceuticals. The AIM-traded company said it

Silence Therapeutics buys stake in US-based Arrowhead Parma

(ShareCast News) - Silence Therapeutics, a developer of ribonucleic acid (RNA) treatments, has bought an 8.4% stake in Nasdaq-listed Arrowowhead Pharmaceuticals for $7.8m ($9.6m). The AIM-listed company bought the minority stake, which represents about 6m shares in the US pharmaceutical's share c

Silence Therapeutics, Quark Pharmaceuticals reach settlement

(ShareCast News) - Silence Therapeutics said it has reached a settlement in the arbitration process with Quark Pharmaceuticals, with the former to receive a $1m cash payment. Under the terms of the agreement, AIM-listed Silence was also eligible to receive either about 2% royalties from Quark plus m

Silence Therapeutics Reaches Settlement With Quark Pharmaceuticals

Silence Therapeutics To Present Gene Editing Data At Berlin Conference